ERBB2 and breast carcinoma: Most evidence has been compiled for these tests to be used for the decision to forego adjuvant chemotherapy in node-negative, ER+HER2− postmenopausal patients (e.g., Oncotype DX, MammaPrint, Endopredict, Prosigna, and Breast Cancer Index).